Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Marketing authorization application submitted for Striant in U.K.

Dec. 9, 2002

ZP-120 completes phase I trial

Dec. 9, 2002

Kissei licenses KUC-7483 to Boehringer Ingelheim

Dec. 2, 2002

Ortho Biotech licenses bone morphogenetic protein technology

Nov. 29, 2002

Effective agents for nephritis without cardiovascular side effects designed at Tanabe Seiyaku

Nov. 28, 2002

Renoprotective effects of ALT-711 in diabetic rats

Nov. 27, 2002

Potential use of pirfenidone in progressive renal disease

Nov. 27, 2002

Positive opinion for Levitra in E.U.

Nov. 26, 2002

FDA requests additional animal study before lifting Vasomax clinical hold

Nov. 26, 2002

Vivus initiates trial of VI-0162 in premature ejaculation

Nov. 25, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...